LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease

• Published in: Movement disorders Vol. 38; no. 3; pp. 386 - 398
• Main Authors: Jennings, Danna, Huntwork‐Rodriguez, Sarah, Vissers, Maurits F.J.M., Daryani, Vinay M., Diaz, Dolores, Goo, Marisa S., Chen, John J., Maciuca, Romeo, Fraser, Kyle, Mabrouk, Omar S., Wetering de Rooij, Jeroen, Heuberger, Jules A.A.C., Groeneveld, Geert Jan, Borin, Marie T., Cruz‐Herranz, Andrés, Graham, Danielle, Scearce‐Levie, Kimberly, De Vicente, Javier, Henry, Anastasia G., Chin, Peter, Ho, Carole, Troyer, Matthew D.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-03-2023; Wiley Subscription Services, Inc
• Subjects: Adverse events; Biomarkers - metabolism; Cerebrospinal fluid; clinical trials; Healthy Volunteers; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - metabolism; Leukocytes, Mononuclear - metabolism; LRRK2 inhibitor; LRRK2 protein; Movement disorders; Mutation; Neurodegenerative diseases; Parkinson Disease - drug therapy; Parkinson Disease - metabolism; Parkinson's disease; Peripheral blood; Pharmacodynamics; Pharmacokinetics; Placebos; Threonine; LRRK2 inhibitor; clinical trials; Parkinson's disease
• ISSN: 0885-3185; 1531-8257
• DOI: 10.1002/mds.29297

Background
Leucine‐rich repeat kinase 2 (LRRK2) inhibition is a promising therapeutic approach for the treatment of Parkinson's disease (PD).
Objective
The aim of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the potent, selective, CNS‐penetrant LRRK2 inhibitor BIIB122 (DNL151) in healthy participants and patients with PD.
Methods
Two randomized, double‐blind, placebo‐controlled studies were completed. The phase 1 study (DNLI‐C‐0001) evaluated single and multiple doses of BIIB122 for up to 28 days in healthy participants. The phase 1b study (DNLI‐C‐0003) evaluated BIIB122 for 28 days in patients with mild to moderate PD. The primary objectives were to investigate the safety, tolerability, and plasma pharmacokinetics of BIIB122. Pharmacodynamic outcomes included peripheral and central target inhibition and lysosomal pathway engagement biomarkers.
Results
A total of 186/184 healthy participants (146/145 BIIB122, 40/39 placebo) and 36/36 patients (26/26 BIIB122, 10/10 placebo) were randomized/treated in the phase 1 and phase 1b studies, respectively. In both studies, BIIB122 was generally well tolerated; no serious adverse events were reported, and the majority of treatment‐emergent adverse events were mild. BIIB122 cerebrospinal fluid/unbound plasma concentration ratio was ~1 (range, 0.7–1.8). Dose‐dependent median reductions from baseline were observed in whole‐blood phosphorylated serine 935 LRRK2 (≤98%), peripheral blood mononuclear cell phosphorylated threonine 73 pRab10 (≤93%), cerebrospinal fluid total LRRK2 (≤50%), and urine bis (monoacylglycerol) phosphate (≤74%).
Conclusions
At generally safe and well‐tolerated doses, BIIB122 achieved substantial peripheral LRRK2 kinase inhibition and modulation of lysosomal pathways downstream of LRRK2, with evidence of CNS distribution and target inhibition. These studies support continued investigation of LRRK2 inhibition with BIIB122 for the treatment of PD. © 2023 Denali Therapeutics Inc and The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.